Video

Dr Sunil Verma Discusses Adding Durvalumab to Cholangiocarcioma Chemotherapy Combination

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses the addition of durvalumab to a chemotherapy regimen of gemcitabine and cisplatin for biliary duct cancer.

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses the addition of durvalumab to a chemotherapy regimen of gemcitabine and cisplatin for biliary duct cancer, as investigated in the TOPAZ-1 trial.

TOPAZ-1 results were initially presented at the recent American Society of Clinical Oncology Gastrointestinal Cancers Symposium and discussed during the Cholangiocarcinoma Foundation 2022 meeting held February 23-25 in Salt Lake City, Utah, and virtually.

Transcript

Can you discuss the mechanism of action of adding durvalumab to gemcitabine/cisplatin chemotherapy in biliary duct cancer?

What we have learned through many other tumor types—including lung cancer, breast cancer, and other emerging tumor types—in certain tumors, single-agent monotherapy IOs [immunotherapies] can be very effective. In melanoma, non–small cell lung cancer with high PD-L1 expression, single-agent monotherapy with IO was very effective.

But in many other tumors, which tend to be much more on the colder range, where the immune system is maybe not as activated, you need chemotherapy to trigger the immune cascade. We identified that biliary tract cancer was likely one of the tumors where we needed a chemotherapy foundation combination to trigger the immune cascade, which would then be enhanced with the combination of checkpoint inhibitors. So in this study, we had a chemotherapy foundation with cisplatin/gemcitabine, and then IO with durvalumab was added on top.

Related Videos
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Emma Achola-Kothari
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Dr Margrit Wiesendanger
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo